Valuation: NeoStem Inc

Market Cap 19.31M 16.98M 15.77M 14.51M 27.21M 1.87B 27.69M 189M 73.57M 912M 72.48M 70.91M 3.16B P/E 2026 *
-1.94x
P/E 2027 * -1.83x
Enterprise Value 19.31M 16.98M 15.77M 14.51M 27.21M 1.87B 27.69M 189M 73.57M 912M 72.48M 70.91M 3.16B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
79.11%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 69 04/01/2015
Director of Finance/CFO 55 31/07/2020
Chief Operating Officer 43 30/04/2016
Director TitleAgeSince
Director/Board Member 69 04/01/2015
Chairman 72 15/02/2017
Director/Board Member 66 31/10/2018
Change 5-day change 1-year change 3-year change Capi.($)
+1.23%+0.35%+51.62%+87.98% 55.27B
+5.09%+6.24%+63.15%+62.06% 54.15B
+0.72%-0.05%+3.84%+409.54% 23.11B
+0.25%+0.55%-19.67%-15.22% 23.22B
+1.03%-0.20%+36.49%-3.59% 20.33B
-0.37%+0.71%+31.36%-31.61% 17.91B
+0.87%-0.19%+39.07%+600.00% 15.76B
-2.54%-8.73%+164.11%+289.45% 15B
+1.22%-0.05%+22.58%+182.63% 13.82B
Average +0.83%+0.71%+43.62%+175.69% 26.51B
Weighted average by Cap. +1.56%+2.77%+44.42%+138.40%

Financials

2026 *2027 *
Net sales - -
Net income -18.3M -16.09M -14.95M -13.75M -25.79M -1.77B -26.25M -179M -69.74M -864M -68.7M -67.22M -3B -21.1M -18.56M -17.24M -15.86M -29.73M -2.04B -30.27M -206M -80.41M -997M -79.21M -77.5M -3.46B
Net Debt - -
Logo NeoStem Inc
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.
Employees
-